However, few EGFR-TKI is effective in treating KRAS-mutant NSCLC due to the special resistance (Pao et al., 2004; Kobayashi et al., 2005; Linardou et al., 2008; Mao et al., 2010). This evidence concerns the gene KRAS and non-small cell lung carcinoma.